Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable

doi:10.7326/0003-4819-156-10-201205150-00013

. 2012 May 15;156(10):743-5.

doi: 10.7326/0003-4819-156-10-201205150-00013.

Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable

Anna S F Lok¹, John W Ward, Robert P Perrillo, Brian J McMahon, T Jake Liang

Affiliations

Affiliation

¹ Division of Gastroenterology and Hepatology, University of Michigan Health System, 3110G Taubman Center, SPC 5368, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA. aslok@umich.edu

PMID: 22586011
PMCID: PMC3469313
DOI: 10.7326/0003-4819-156-10-201205150-00013

Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable

Anna S F Lok et al. Ann Intern Med. 2012.

. 2012 May 15;156(10):743-5.

doi: 10.7326/0003-4819-156-10-201205150-00013.

Authors

Anna S F Lok¹, John W Ward, Robert P Perrillo, Brian J McMahon, T Jake Liang

Affiliation

¹ Division of Gastroenterology and Hepatology, University of Michigan Health System, 3110G Taubman Center, SPC 5368, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA. aslok@umich.edu

PMID: 22586011
PMCID: PMC3469313
DOI: 10.7326/0003-4819-156-10-201205150-00013

No abstract available

PubMed Disclaimer

Cited by

Reactivation of hepatitis C virus caused by steroid monotherapy for sudden deafness.
Kaneko H, Ozono Y, Iwakiri H, Hatada H, Uchiyama N, Komaki Y, Nakamura K, Hasuike S, Nagata K, Kawakami H. Kaneko H, et al. Clin J Gastroenterol. 2024 Jun;17(3):505-510. doi: 10.1007/s12328-024-01944-9. Epub 2024 Apr 8. Clin J Gastroenterol. 2024. PMID: 38587568 Free PMC article.
Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments.
Köksal AŞ, Toka B, Sadeçolak M, Acar Ş, Eminler AT, Tozlu M, Karabay O. Köksal AŞ, et al. Turk J Gastroenterol. 2023 May;34(5):552-559. doi: 10.5152/tjg.2023.22297. Turk J Gastroenterol. 2023. PMID: 36939611 Free PMC article.
COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature.
Sagnelli C, Montella L, Grimaldi P, Pisaturo M, Alessio L, De Pascalis S, Sagnelli E, Coppola N. Sagnelli C, et al. Pathogens. 2022 Jul 21;11(7):816. doi: 10.3390/pathogens11070816. Pathogens. 2022. PMID: 35890060 Free PMC article. Review.
Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study.
Mohareb AM, Patel NJ, Fu X, Kim AY, Wallace ZS, Hyle EP. Mohareb AM, et al. J Rheumatol. 2022 Jan;49(1):104-109. doi: 10.3899/jrheum.210257. Epub 2021 Aug 1. J Rheumatol. 2022. PMID: 34334359 Free PMC article.
Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges.
Yeh H, Chiang CC, Yen TH. Yeh H, et al. World J Gastroenterol. 2021 Jul 14;27(26):4104-4142. doi: 10.3748/wjg.v27.i26.4104. World J Gastroenterol. 2021. PMID: 34326614 Free PMC article. Review.

See all "Cited by" articles

References

1. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156–65. [PMID: 19399803] - PubMed
1. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemo-therapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299–307. [PMID: 11055239] - PubMed
1. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29:1021–9. [PMID: 20556450] - PubMed
1. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002;36:1246–52. [PMID: 12395336] - PubMed
1. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphopro-liferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22:1170–80. [PMID: 21115603] - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

ZIA DK054500-16/ImNIH/Intramural NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156–65. [PMID: 19399803] - PubMed

[2] Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156–65. [PMID: 19399803] - PubMed

[3] Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemo-therapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299–307. [PMID: 11055239] - PubMed

[4] Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemo-therapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299–307. [PMID: 11055239] - PubMed

[5] Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29:1021–9. [PMID: 20556450] - PubMed

[6] Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29:1021–9. [PMID: 20556450] - PubMed

[7] Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002;36:1246–52. [PMID: 12395336] - PubMed

[8] Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002;36:1246–52. [PMID: 12395336] - PubMed

[9] Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphopro-liferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22:1170–80. [PMID: 21115603] - PMC - PubMed

[10] Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphopro-liferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22:1170–80. [PMID: 21115603] - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable

Affiliation

Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable

Authors

Affiliation

Similar articles

Cited by

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Similar articles

Cited by

References

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical